What is known about the Ebola outbreak in the Democratic Republic of Congo—including why it is the deadliest and fastest growing outbreak on record, with more than 5,000 infections and 2,500 deaths; the arrival and planned use of 70,000 doses of Merck’s Ervebo vaccine, including

As of 20 August, the DRC had reported 5,290 confirmed Bundibugyo Ebola cases and 2,516 deaths—a roughly 48% confirmed-case fatality ratio. It is the DRC’s deadliest recorded Ebola outbreak and is expanding faster than any of its prior Ebola outbreaks. 1

• Why response is unusually difficult: The outbreak involves Bundibugyo ebolavirus, for which there is no licensed vaccine or specific treatment. The WHO also describes a challenging humanitarian setting, which constrains surveillance, isolation, contact tracing, safe burials, staffing, and logistics. Those factors—not merely the virus’s intrinsic severity—help explain why conventional containment has not kept pace. 15

• Ervebo deployment: WHO’s international coordinating mechanism allocated 70,000 doses of Merck’s Ervebo, and the first shipment of 16,250 doses reached Kinshasa on 22 August. 310 Ervebo is licensed for Zaire ebolavirus, not Bundibugyo; its effectiveness against the strain now circulating in the DRC is unproven in humans. 615

• Planned use and trial: Reporting describes 50,000 doses intended for frontline/community protection and 20,000 for a Phase 3 study. The trial is therefore important both as an emergency response and as a way to establish whether Ervebo offers meaningful cross-protection against Bundibugyo. The key caveat is that the trial cannot establish protection immediately, while transmission is already intense. 36

• New strain-matched vaccines: Oxford has already begun a Phase 1 trial of its ChAdOx1 Bundibugyo candidate in healthy adults, assessing safety and immune responses. 25 Moderna also began a first-in-human trial in early August. 4 I could not independently confirm from the retrieved primary or high-quality sources the specific timeline or development status for an IAVI candidate; in general, early-stage trials cannot supply doses quickly enough to determine the near-term course of this outbreak.

• Limits of current measures and WHO action: Isolation and contact tracing remain essential, but the number of new cases, the lack of a proven Bundibugyo countermeasure, and operational constraints mean they are insufficient on their own at present. WHO has characterized the outbreak as being in “intense transmission”; detailed new WHO recommendations beyond the standard response pillars were not established in the material reviewed. 15

• Canada: Canada’s measures require citizens and permanent residents recently in the DRC to complete a 21-day quarantine and bar other recent DRC travellers, subject to exemptions; they are scheduled to expire at 23:59 EDT on 29 August. 148 Humanitarian groups argue this deters deployment: reporting says at least 11 Médecins Sans Frontières/Doctors Without Borders personnel cancelled assignments. 8 Critics also contrast Canada’s reported $8 million response with more than $110 million contributed during the 2014 West Africa epidemic. 9

• Travel-policy dispute: The criticism is that blanket entry restrictions and mandatory quarantine can reduce the very specialist workforce needed at the outbreak’s source, while WHO guidance generally favors evidence-based screening, monitoring and rapid care over indiscriminate travel restrictions. Canada says it is reviewing the restrictions and current evidence before the expiry date. 8

The central uncertainty is whether Ervebo has enough cross-protection to slow transmission before Bundibugyo-specific candidates can progress beyond early human testing.